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Abstract
Objective: Utilization of pharmacogenomics data in clinical practice is a critical step toward individual and 
precision medicine. This is a cross-sectional study conducted by incorporating several variables as outlined 
in the survey report to assess and analyze the reasons or behaviors that could influence clinicians to use 
or not use pharmacogenomics. Materials and Methods: In this study, we conducted a cross-sectional 
quantitative survey among primary physicians practicing in Kettering Health Network facilities. 1201 
invitations were sent out and 135 physicians participated in the survey. Physicians were requested by 
email to participate in a survey containing 14 multiple choice questions regarding their understanding and 
beliefs regarding pharmacogenomics, as well as questions about specific professional details which were 
intended to explore how physician characteristics affected familiarity, and comfort and confidence in using 
pharmacogenomics data inpatient care. Statistical Package for the Social Sciences (standard version 25) 
was used for statistical analysis, and consent was obtained from all study participants through the survey 
link. Results: The ratings of the familiarly, comfort, and confidence with pharmacogenetics were highly 
intercorrelated (r = 0.81–0.87). Accordingly, we summed the three ratings to form a composite score of 
the three items; hereafter referred to as “scale scores.” Possible scores ranged from 5 to 15, whereas 
actual scores ranged from 3 to 15 (Mean = 6.32, SD = 3.12). Scale scores were not statistically significantly 
correlated with age (r = 0.12, P < 0.17) or number of years in practice (r = 0.11, P < 0.22), and were only 
weakly (inversely) correlated with number of hours spent in patient care each week (r = −0.17, P < 0.05). 
Conclusion: In our study, physicians who had some education in the field of pharmacogenomics were more 
likely to use pharmacogenomics data in clinical practice. We have further characterized that continuing 
medical education (CME), more than medical education or residency training significantly predicts 
familiarity, confidence or comfort in using pharmacogenomics data. Therefore, pharmacogenomics should 
be integrated in the CME for practicing clinicians as well as graduate medical education.
Keywords: Clinical practice, Continuing medical education, Cross-sectional study, Graduate medical 
education, Pharmacogenomics data, Pharmacogenomics testing, Pharmacogenomics, Precision medicine
Introduction
Pharmacogenomics is the study of how interindividual 
variability in genes affects drug response.[1,2] It has 
also been found that greater than half of drugs with 
known drug adverse reaction are metabolized by 
polymorphic enzymes.[3] Furthermore, adverse drug 
reactions have been found to be the fifth leading 
cause of death in the United States.[4]
The utility of pharmacogenomics is essential to 
tailor treatment on the basis of genetic profile. By 
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understanding the genetic profiles of individual 
patients, we could also have a greater understanding 
of responsiveness to a given drug before starting it. 
Since pharmacogenomics has become an integral 
part of precision medicine, the potential impacts 
include decreasing morbidity and mortality as well 
as promoting cost effectiveness.
Since the conception of pharmacogenomics, it 
has become more apparent genetics contributed 
to the varying drug responses in several ways.[5] 
To this day, genomic information is continuously 
being generated in laboratories and integrated into 
electronic medical records. Automatic computer-
based alerts that “fire” is a method to help 
consider a pharmacogenomics test when a drug 
is prescribed. 1,5] One study known as the “RIGHT” 
protocol, done by the Mayo Clinic, also relied on 
receiving “alerts” that informed the provider with 
patient’s gene sequence.[5] Another study, the “1200 
Patients Project,” was done by Peter H. O’Donnell 
et al. Where a web-based “Genomic Prescribing 
System” (GPS) can provide a clinical interpretation 
of patient’s genomic data for a given drug which can 
be accessible to the provider in a short summary.[4,6] 
These are a few out of many efforts to analyze our 
current understanding of pharmacogenomics and 
its potential impact for the future.
Yet, a number of barriers prevent optimal utilization 
of pharmacogenomics into clinical practice. 
These include the availability of testing, the lack 
of evidence-based guidelines for prescribing, 
the ability to incorporate results into electronic 
medical records, and the education of health 
providers.[1] According to the results of the 
RIGHT protocol, among primary care clinicians 
participated, 30% noted that pharmacogenomics 
were part of their formal training and education; 
9% had discussed pharmacogenomics results with 
a patient; 52% did not plan to use or were unsure 
if they would use pharmacogenomics results in the 
future, and 7% expected to order or recommend a 
pharmacogenomics test for patients in the next 6 
months.[1]
Physicians’ current level of comfort to utilize 
pharmacogenomics, notably in the community 
setting, is a concern. At present, there is very little 
data examining correlations between physician 
comfort level to use pharmacogenomics and 
willingness to use it in clinical practice. In this study, 
a survey was conducted, incorporating a number of 
factors (age, number of articles read, conferences 
attended, and other variables as outline in the 
survey report) to assess reasons or behaviors 
that could influence clinicians to use or not use 
pharmacogenomics.
Materials and Methods
Our study consisted of a survey that was 
anonymously and voluntarily completed by 
physicians practicing in Kettering Health Network 
facilities. Physicians were requested by email to 
participate in a survey, containing 14 multiple 
choice questions regarding their understanding 
and beliefs regarding pharmacogenomics, as well 
as questions about specific professional details 
which were intended to explore how physician 
characteristics affected familiarity, and comfort 
and confidence in using pharmacogenomics data 
inpatient care. 1201 invitations were sent out, 
and 135 physicians participated in the study. 
Online platform SurveyMonkey was utilized for the 
development and distribution of online surveys 
as well as the extraction of survey responses and 
de-identification of respondents. All participants 
provided informed consent by clicking on a link 
embedded in the survey invitation email. The 
survey form is described in Appendix 1. This study is 
a quality improvement study and it is exempt from 
the institutional ethics review.
Initially, emails, including a hyperlink to the survey, 
were disseminated by administrative personnel 
in the Medical Staff office to physicians on both 
Kettering and Non-Kettering Physician Networks. On 
February 22, 2017, the emails were sent out using 
group emails without any intentional selection or 
exclusion process. To increase participation, follow-
up email reminding physicians of the survey was 
sent out on March 3, 2017. The survey data were 
collected from February 22, 2017, to March 10, 
2017. The data were then analyzed to assess for 
any significant relationship between participant 
variables and resulting survey data. Statistical 
Package for the Social Sciences (standard version 25) 
was used for statistical analysis. Initial data analyses 
consisted of calculating relevant Pearson correlation 
coefficients for relationships between and among 
continuous variables, and one-way analyses of 
variance for comparison of means between the two 
groups. A composite score of familiarity, comfort, 
and confidence with pharmacogenetics “scale 
scores” was summed after these three variables 
were found to be highly intercorrelated. The degree 
of correlation between physician variables and 
the scale scores was calculated using regression 
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analysis with P < 0.05 used to determine statistical 
significance. Analysis of variance (ANOVA) was used 
to determine the relationships between categorical 
variables and scale scores, and Bonferroni post 
hoc analysis was used to correct for possible false 
discovery.
Results
The survey was completed by 135 physicians. 
The sample size was adjusted to reflect the 
nonresponse rate in each section. With reference to 
the age distribution of the study participants, most 
participants were between 25 and 34 years of age; 
with the least falling within the range of 65 years 
and above [Figure 1]. The medical specialty with the 
most participants was general internal medicine. 
Although, seven participants failed to identify their 
specialty [Figure 2]. The familiarity, comfort, and 
confidence ratings with pharmacogenetics were 
highly intercorrelated (r = 0.81–0.87). Accordingly, 
we summed the three ratings to form a composite 
score of the three items (hereafter referred to as 
“scale scores”). Possible scores ranged from 5 to 
15, whereas actual scores ranged from 3 to 15 
(Mean = 6.32, SD = 3.12).
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Scale scores were not statistically significant 
correlated with age (r = 0.12, P < 0.17) or number 
of years in practice (r = 0.11, P < 0.22) and were 
only weakly (inversely) correlated with number 
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Figure 1: Age distribution of participants 
(Non-response rate = 2 participants failed to 
indicate their age group)
Figure 2: Medical specialty of participants (Non-response rate = 7; Adjusted sample size = 128). 
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(r = −0.17, P < 0.05). Men (Mean = 6.38, SD = 3.18) and 
women (Mean = 6.20, SD = 3.03) did not statistically 
significant differ in scale scores, F (1,130) = 0.11, 
P < 0.75. However, scale scores were statistically 
significant correlated with rated job satisfaction 
(r = 0.27, P < 0.002), the number of journal articles 
read per month (r = 0.28, P < 0.002), and the number 
of medical conferences attended per year (r = 0.21, 
P < 0.02). Scale scores were statistically significant 
greater among respondents who had encountered 
patients with drug metabolizing gene variants 
(Mean = 7.26, SD = 3.24) compared to those who 
had not (Mean = 5.60, SD = 2.83), F (1,130) = 9.84, 
P < 0.01.
Medical specialty of participants based on the 
survey response
Medical specialty Response rate  
(Non-response rate=7; 
Adjusted n=128)
Family medicine 14.06% (18)
General internal medicine 33.59% (43)
Cardiology 8.59% (11)
Pulmonology 1.56% (2)
Hematology and oncology 1.56% (2)
Rheumatology 0.78% (1)





General surgery 1.56% (2)
Surgical subspecialties 11.72% (15)
Anesthesiology 2.34% (3)
Dermatology 0.00% (0)
Emergency medicine 8.59% (11)
Pediatrics 0.00% (0)
Obstetrics and gynecology 0.00% (0)
Total 100% (128)
With regard to scale scores as a function of ever 
having received training in pharmacogenetics, 
those reporting such training (Mean = 8.12, 
SD = 3.11) had statistically significantly higher 
scores compared to those who reported never 
having received such training (Mean = 4.95, 
SD = 2.34), F (1,130) = 44.90, P < 0.001. Among 
those who had received some training, an overall 
ANOVA revealed that the three groups were 
statistically significant different, F (2, 54) = 6.04, 
P < 0.01. Bonferroni post hoc comparisons revealed 
that scale scores among those who received 
training through continuing medical education 
(CME) (Mean = 9.18, SD = 2.93) were greater than 
scale scores among those who received training 
during medical school (Mean = 6.25, SD = 2.93, 
P < 0.01) but not statistically significant different 
from scale scores of those who received training 
in residency (Mean = 7.29, SD = 2.22, P < 0.36). 
Scale scores of those who received training during 
medical school or residency were not statistically 
significant different (P < 1.00).
Because of overlap among the variables found 
to be statistically significant related to the scale 
scores, we performed a multiple regression 
analysis in which the predictor variables were 
the number of hours spent inpatient care each 
week, rated job satisfaction, having encountered 
patients with drug-metabolizing gene variants, 
the number of journal articles read per month, 
and the number of medical conferences attended 
per year were entered simultaneously. The overall 
regression equation was statistically significant, 
F (6,124) = 13.20, P < 0.001. However, only 
three predictor variables exhibited independent 
relationships with the scale scores: Having ever 
received training (Standardized Beta = 0.46, 
P < 0.01), having encountered patients with 
drug-metabolizing gene variants (Standardized 
Beta = 0.18, P < 0.02), and rated job satisfaction 
(Standardized Beta = 0.66, P < 0.03).
Other survey items and participant response rate
1. How many years have you been in practice?
Number 
of years
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2. How many hours per week do you spend in 
direct patient care?
Hours per week 












3. How many medical journals/articles do you 
read per month?
Number of medical 
journals/articles read 
monthly









4. How many medical conferences/meetings do 












5. Rate your job satisfaction from 1 (least) to 5 
(most).
Level of job 
satisfaction






















7. How confident are you in your knowledge of 
pharmacogenomics? (1=least 5=most)
Confidence in level 
of knowledge of 
pharmacogenomics









8. How comfortable are you in using 
pharmacogenomics? (1=least 5=most)
Level of comfort 
with regards to using 
pharmacogenomics









9. Where did you receive your pharmacogenomics 
training?
Site of training Response rate (Non-response 
rate=1; Adjusted n=134)
Did not receive 
training
56.72% (76)
Medical School 11.94% (16)
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10. Have you encountered any patients with drug 
metabolizing gene variants?





11. How confident are you in your knowledge of 




Response rate (Non-response 
rate=1; Adjusted n=134)
Not confident 44.78% (60)
Slightly confident 26.87% (36)
Somewhat confident 20.15% (27)
Quite confident 8.21% (11)
Very confident 0.00% (0)
Total 100% (134)
Discussion
In 2015, St. Sauver et al. assessed the response of 
159 primary care providers to pharmacogenomics 
clinical decision support alert in the electronic 
health records. Over half of the clinicians did not 
expect to use pharmacogenomics data in the future 
or did not see the utility of pharmacogenomics 
information in their future prescribing practices. 
This was in contrast to the patient’s expectation 
that providers will tailor their drug therapy to 
fit the pharmacogenomics profile.[7] Their group 
hypothesized that education in pharmacogenomics 
could potentially lead to increased satisfaction with 
pharmacogenomics alerts.[7] It was not clear how 
half of the providers who were uncomfortable with 
pharmacogenomics and its alerts were different 
from their cohort. We had theorized that to increase 
participation of physicians in the implementation of 
pharmacogenomics in everyday practice it will be 
important to understand physician demographic and 
behavioral factors that will affect their interaction 
with pharmacogenomics in their clinical practice. 
This study has successfully characterized physician 
factors that will affect the familiarity, comfort, and 
confidence in using pharmacogenomics data in 
practice.
Using scaled score for familiarity, comfort, and 
confidence, we have shown that physicians’ 
age does not predict their interaction with 
pharmacogenomics data (r = 0.12, P < 0.17). The 
commonly held notion that older physicians may be 
slow to use innovation was not supported by our 
data, at least, not in the field of pharmacogenomics. 
Neither did the data suggest that physicians who 
spent more time in patient care were more likely 
to use pharmacodynamics data to affect therapy 
(r = −0.17, P < 0.05).
Interestingly, a physician’s self-rated job satisfaction 
correlated significantly to familiarity, confidence, 
and comfort in using pharmacogenomics 
information (r = 0.27, P < 0.002). This finding has 
hitherto not been shown in the medical literature. 
The exact reason why job satisfaction correlates so 
strongly to confidence in using pharmacogenomics 
data is not entirely clear at this point. In fact, it is not 
yet known in the medical literature the relationship 
between job satisfaction and acceptance of new 
health innovation. There is, thus, opportunity for 
further research to clarify to interesting correlation.
In our study, physicians who had some education 
in the field of pharmacogenomics were more 
likely to use pharmacogenomics data in clinical 
practice. The previous studies had alluded to 
this fact.[7,8] What was not clear was the kind of 
education that predicted familiarity, confidence, 
and comfort in using pharmacogenomics. We 
have further characterized that CME, more 
than medical education, or residency training 
significantly predicts familiarity, confidence, or 
comfort in using pharmacogenomics data. This 
adds validity to the conclusion of Reed et al. that 
adult learning principles is an appropriate model 
to deliver pharmacogenomics education to health 
professionals.[7] In the United States, members 
of NIH’s Pharmacogenomics Research Network 
have organized a Translational Pharmacogenomics 
Project that has been working on best practice 
guidelines that they seek to share with clinicians for 
proper integration of pharmacogenomics data into 
practice.[4,7-14]
This study adds new insight to our already expanding 
knowledge of ways to implement pharmacogenomics 
data in clinical practice. However, there are some 
limitations worth mentioning. This is a small single-
center study; larger studies are needed to replicate 
these findings. Furthermore, this study was 
conducted in a community health network, whereas 
the majority of implementation studies have been 
conducted in large university hospitals. It is unclear 
whether physician characteristics found in our study 
can be extrapolated to physicians in university 
hospitals.[4,6,15-17] Exclusion of non-physician primary 
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care providers, such as nurse practitioners and 
physician assistants, is another limiting factor of this 
study.
Conclusion
In our study, physicians who had some education 
in the field of pharmacogenomics were more likely 
to use pharmacogenomics data in clinical practice. 
We have further characterized that CME, more than 
medical education or residency training significantly 
predicts familiarity, confidence, or comfort in using 
pharmacogenomics data.
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